TP53 R158L

CI-VAR-00003684Explore in graph →ENST00000269305.4:c.473G>TClinVar 528248 CIViC 1699 rs587782144

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
TP53 R158L	MDM2 Inhibitor AMGMDS3	Predictive	D	Supports Resistance	3	accepted	EID4891 Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP… (full text at CIViC) PMID 25730903 · Saiki et al., 2015 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
528248	Pathogenic	reviewed by expert panel	3	Li-Fraumeni syndrome; Hereditary cancer-predisposing syndrome; Li-Fraumeni syndrome 1; Diffuse midline glioma, H3 K27M-mutant	germline/somatic	10	Dec 05, 2025	clinvar